Thyrocare Technologies Share News - Latest Updates, Live News & More

Latest news about Thyrocare Technologies

Docon Technologies Pledges Thyrocare's Bonus Shares to Secure API Holdings' Debentures 1 day ago

Docon Technologies, a subsidiary of API Holdings, has pledged 6,46,46,464 bonus shares of Thyrocare Technologies to secure debentures issued by API Holdings. The pledge, made on December 02, 2025, maintains the same 60.93% encumbered shareholding percentage despite the increased number of shares due to a recent 2:1 bonus issue. This action complies with SEBI regulations and has been disclosed to the National Stock Exchange and BSE.

Thyrocare Technologies' Chief Commercial Officer Nitin Chugh Steps Down 5 days ago

Thyrocare Technologies Sets Record Date for 2:1 Bonus Share Issue Nov 16, 2025

API Holdings Redeems ₹500 Crore NCDs, Thyrocare Share Pledge Remains Intact Nov 12, 2025

Docon Technologies Reduces Stake in Thyrocare, Maintains Promoter Status Oct 28, 2025

More news about Thyrocare Technologies

27Oct 25

ICICI Prudential Mutual Fund Boosts Stake in Thyrocare Technologies to Over 5%

ICICI Prudential Mutual Fund has increased its stake in Thyrocare Technologies from 1.56% to 5.33% through secondary market purchases. The fund acquired 19,98,400 shares on October 24, 2025, bringing its total shareholding to 28,23,890 shares. This move is described as a purely investment-driven decision, with no intention to seek controlling interest in the diagnostic services company. Thyrocare Technologies has a total equity share capital of ₹52,99,44,470, divided into 5,29,94,447 shares with a face value of ₹10 each.

24Oct 25

Thyrocare Promoter Docon Technologies Offloads 10% Stake for Rs 667.69 Crore

Docon Technologies Private Limited, a promoter of Thyrocare Technologies Limited, has sold 53,32,860 equity shares (approximately 10% of total paid-up capital) at an average price of Rs 1,252.03 per share, totaling Rs 667.69 crore. The transaction, executed on October 24, 2025, reduces the promoter shareholding from 70.98% to 60.93%. Despite the sale, Docon Technologies remains a promoter of Thyrocare. The company disclosed this information in compliance with SEBI regulations.

17Oct 25

Thyrocare Reports 22% Revenue Growth, Announces 2:1 Bonus Issue and Interim Dividend

Thyrocare Technologies posted a 22% YoY growth in Q2 FY26 consolidated revenue at INR 217.00 crores. The company's core pathology business grew 24% YoY, while partnerships business expanded by 35%. Operational highlights include a 21% increase in processed tests and a 12% rise in patients served. The Board approved a 2:1 bonus share issue and declared an interim dividend of INR 7.00 per share. Thyrocare expanded its franchise network to 10,100 active franchisees and improved service quality, achieving Six Sigma levels. The company's Aarogyam and Jaanch segments showed strong growth. Management remains cautious about future guidance due to seasonal variations and market dynamics.

16Oct 25

Thyrocare Technologies Announces 2:1 Bonus Share Issue and Capital Increase

Thyrocare Technologies Limited has announced plans for a 2:1 bonus share issue and an increase in authorized share capital from Rs. 100 crores to Rs. 300 crores. The company will capitalize approximately Rs. 106.11 crores from reserves for the bonus issue. Shareholders will vote on these proposals through a postal ballot, with e-voting scheduled from October 18 to November 16, 2025. The company also plans to make adjustments to employee stock options to maintain their value post-bonus issue. These actions are subject to shareholder approval and regulatory clearances.

15Oct 25

Thyrocare Technologies Surges 16% on Strong Q2 Results; Announces 2:1 Bonus Issue and Interim Dividend

Thyrocare Technologies' shares reached a 52-week high of Rs 1,470, up 16%, following impressive Q2 results. The company reported an 82% YoY increase in profit after tax to Rs 47.90 crore, and a 22% rise in revenue to Rs 216.53 crore. Normalized EBITDA grew 49% to Rs 75.36 crore. The Pathology segment saw 24% growth, with franchise revenue up 20% and partnership revenue up 35%. Thyrocare processed 53.3 million tests, a 21% YoY increase. The company expanded its network with four new laboratories. The Board approved a 2:1 bonus share issue and declared an interim dividend of Rs 7 per share. Thyrocare remains debt-free with over Rs 190 crore in net cash and short-term investments.

15Oct 25

Thyrocare Tech Reports Strong Q2 Results, Declares Bonus Shares and Interim Dividend

Thyrocare Technologies Limited reported robust Q2 financial results with 22% YoY revenue growth to Rs 216.53 crore, 49% EBITDA growth to Rs 75.36 crore, and 82% PAT growth to Rs 47.90 crore. The company processed 53.3 million tests, up 21% YoY. The Board approved a 2:1 bonus share issue and declared an interim dividend of Rs 7 per share. Thyrocare expanded its network with four new laboratories and maintains a strong balance sheet with over Rs 190 crore in net cash and short-term investments.

14Oct 25

Thyrocare Technologies Posts Impressive Q2 Results: Net Profit Surges 80%, Revenue Up 23%

Thyrocare Technologies posted robust Q2 FY2024 results with net profit soaring 80% to ₹48.00 crore. Revenue increased by 23% to ₹217.00 crore, while EBITDA grew 47.80% to ₹71.35 crore. The company's EBITDA margin expanded significantly to 32.95%, up by 570 basis points year-over-year, indicating improved operational efficiency.

14Oct 25

Thyrocare Technologies Announces 2:1 Bonus Share Issue and Rs 7 Interim Dividend

Thyrocare Technologies Limited has announced several corporate actions as part of its Silver Jubilee celebrations. The company reported revenue of Rs 202.23 crores and profit of Rs 43.03 crores for the quarter ended September 30. Key announcements include a 2:1 bonus share issue, an interim dividend of Rs 7 per share, plans to increase authorized share capital from Rs 100 crores to Rs 300 crores, allotment of 59,450 equity shares under employee stock options, and reappointment of Ernst & Young as internal auditors. The record date for dividend eligibility is set as October 24.

26Sept 25

Thyrocare Technologies Appoints Alok Kumar Jagnani as Non-Executive Director with Overwhelming Shareholder Approval

Thyrocare Technologies Limited has appointed Mr. Alok Kumar Jagnani as a Non-Executive and Non-Independent Director through a postal ballot and e-voting process. The appointment received overwhelming support with 99.92% of shareholders voting in favor. The remote e-voting period ran from August 28 to September 26, with a total of 4,57,32,435 valid votes cast. The scrutinizer's report confirmed the resolution's approval with the required majority. Separately, Thyrocare announced the closure of the trading window for insiders from October 01 until 48 hours after the announcement of Q2 financial results.

19Sept 25

Thyrocare Technologies: Promoter Pledges 60.99% Stake to Secure Debentures

Docon Technologies, the promoter of Thyrocare Technologies, has pledged 3,23,23,232 equity shares (60.99% of total share capital) to Catalyst Trusteeship Limited. This pledge secures new debentures issued by API Holdings Ltd., Thyrocare's ultimate holding company. The transaction, completed on September 17, doesn't alter Thyrocare's ownership structure but encumbers a significant portion of promoter holdings. Thyrocare's equity share capital remains at Rs. 52.99 crore.

18Sept 25

Thyrocare Technologies: Vistra ITCL Releases 71.06% Stake Pledge

Vistra ITCL (India) Limited, acting as Debenture Trustee, has released its pledge on 3,76,56,092 equity shares of Thyrocare Technologies Limited, representing 71.06% of the company's total voting capital. The pledge release occurred on September 16, 2025, reducing Vistra's encumbered shareholding in Thyrocare to nil. This action affects a significant portion of Thyrocare's total equity share capital of 5,29,94,447 shares. The disclosure was filed in compliance with SEBI regulations on September 18, 2025.

15Sept 25

API Holdings to Issue INR 1,700 Crore Debentures, Docon to Pledge Up to 61% of Thyrocare Shares

API Holdings Limited, the ultimate holding company of Thyrocare Technologies, plans to issue new secured, unlisted, redeemable non-convertible debentures worth INR 1,700 crore. The purpose is to redeem existing debentures valued at INR 1,545.38 crore. Docon Technologies, holding 71.06% of Thyrocare's equity, will pledge up to 61% of Thyrocare's shares as security. The transaction involves multiple parties and agreements, executed on September 11. While not directly impacting Thyrocare's current management, potential control changes could occur if the pledge is enforced upon default.

25Aug 25

Thyrocare Technologies Seeks Shareholder Approval for Appointment of Alok Kumar Jagnani as Non-Executive Director

Thyrocare Technologies has initiated a postal ballot to appoint Alok Kumar Jagnani as a Non-Executive & Non-Independent Director. Jagnani, with over 20 years of experience, previously served as Thyrocare's CFO and is now Group CFO at API Holdings Limited. The e-voting period for shareholders is from August 28 to September 26, 2025. Jagnani will serve on multiple board committees and holds 2,443 equity shares in the company. He will not receive remuneration for this non-executive role.

06Aug 25

Thyrocare's Rahul Guha to Lead API Holdings as CEO While Retaining Current Role

Rahul Guha, current MD and CEO of Thyrocare Technologies, will additionally become MD and CEO of API Holdings from August 27, 2025. He will maintain his position at Thyrocare while taking on new responsibilities at API Holdings. Siddharth Shah, current MD and CEO of API Holdings, will be re-designated as Director and Vice Chairman. This move aims to enhance synergies between Thyrocare and its parent company, API Holdings.

30Jun 25

Thyrocare Technologies Faces ₹133.1 Crore Tax Demand

Thyrocare Technologies Ltd., a leading diagnostics and preventive healthcare service provider, has received two significant tax demands totaling ₹133.10 crore. The demands include ₹2.10 crore and ₹131.00 crore. The company's disclosure lacks specific details about the nature of these demands, the tax periods involved, or the grounds for the claims. This substantial tax liability could potentially impact Thyrocare's financial position, cash flow management, and future planning.

23Apr 25

Thyrocare Technologies Reports Strong Growth in Q4 and FY25, Achieves 100% NABL Accreditation

Thyrocare Technologies Limited announced robust financial results for Q4 and FY25. Q4 saw a 21% YoY revenue increase to INR 187.20 crore, with 78% EBITDA growth and 88% PAT surge. FY25 annual revenue rose 20% to INR 687.30 crore, with 37% EBITDA growth and 45% PAT increase. The company became India's first 100% NABL accredited national diagnostic lab chain, processed 167.9 million tests, and expanded its franchisee network. Strategic acquisitions of Polo Labs and Vimta Labs' diagnostic business were completed. The Board recommended a final dividend of INR 21.00 per share.

03Mar 25

Thyrocare Technologies Strengthens Tanzanian Joint Venture with $25,000 Investment

Thyrocare Technologies has invested an additional $25,000 (₹21.98 lakh) in its Tanzanian joint venture, Thyrocare Laboratories (Tanzania) Limited. This investment is part of a larger ₹15 crore plan. The joint venture, operational since April 2024, reported a turnover of ₹0.44 crore for the nine months ended December 31, 2024. With this investment, Thyrocare's stake temporarily exceeds 50%, potentially making the joint venture a subsidiary. The shareholding is expected to revert to 50:50 once partners contribute their equity portion.